New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
09:24 EDTSLXPSalix should be bought ahead of catalysts, says Sterne Agee
Sterne Agee believes that the upcoming FDA Advisory Committee on Relistor, scheduled for June 11-12, and the TARGET 3 clinical trial data on Xifaxan, expected in early July, provide important near-term catalysts for Salix. The firm recommends that investors buy Salix ahead of these events. It increased its price target on the stock to $130 from $126.
News For SLXP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
12:34 EDTSLXPSalix mentioned as a potential acquisition target by dealReporter
November 14, 2014
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
06:03 EDTSLXPSalix upgraded to Buy from Neutral at UBS
UBS upgraded Salix Pharmaceuticals to Buy saying it believes management has a better handle on inventory levels than investors think. The sees opportunity at current share levels and lowered its price target for shares to $116 from $160.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use